IND-enabling safety tox studies for FDA submission in just 9 months

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.

Author

Latest Blogs

Syngene booth at CPHI Japan 2026 with visitors and team members in discussion

CPHI Japan 2026 Takeaways: Why supply chain diversification is redefining CDMO trust in Japan

Decoding the FDA’s AMT program through process analytical technology

Infographic showing gene editing applications across the drug development pipeline.

Gene editing in 2025: from CRISPR to next generation platforms

AI drug discovery workflow for small molecule design

AI Drug Discovery: The Future of Small Molecule Design

Tirbanibulin and targeted dermal delivery in topical drug development

Therapeutics 2.0: Veterinary Oncology and Peptide Conjugates for Companion Animal Health

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details